Market Access UCB brings first therapy for rare disease TK2d to EU PharmaphorumThe EU has approved UCB's Kygevvi for rare disease TK2d, and Sanofi's acute GvHD therapy Rezurock, in a pair of decisions announced this morning.Market AccessRare DiseaseRead full story pharminent March 31, 2026 (Last updated: March 31, 2026) Pharmaphorum The EU has approved UCB’s Kygevvi for rare disease TK2d, and Sanofi’s acute GvHD therapy Rezurock, in a pair of decisions announced this morning. Market AccessRare DiseaseRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team PhotoNext: Merck strikes deal with antibody discovery startup Related Stories Market Access pharminent June 12, 2026 Market Access Aquipta recommended by NICE for acute migraine treatment pharminent June 10, 2026 Market Access AbbVie’s migraine drug cleared for migraine attacks on NHS pharminent June 10, 2026
